Clevidipine elimination is unlikely to be affected by renal dysfunction due to its rapid metabolism in the blood and extravascular tissues.

The clevidipine infusion may be titrated by doubling the dose at short (as early as 90 seconds) intervals initially. As the blood pressure approaches goal, the dose titration should be less than doubling and the time between dose adjustments should be lengthened to every 5-10 minutes. Individualize the clevidipine dosage depending on the blood pressure response of the patient and the goal blood pressure. Monitor blood pressure and heart rate continually during infusion, and then until vital signs are stable.

Clevidipine may produce systemic hypotension and reflex tachycardia. If either occurs, decrease the dose of clevidipine.

Clevidipine is a lipid emulsion that contains approximately 2.0 kcal (0.2 g) of lipid per mL.

Due to the lipid content, clevidipine is contraindicated in patients with defective lipid metabolism such as:

• pathologic hyperlipemia,
• lipoid nephrosis,
• or acute pancreatitis if it is accompanied by hyperlipidemia

Because of lipid load restrictions, no more than 1000 mL or an average of 21 mg/hour of Cleviprex infusion is recommended per 24 hour period.